OverviewSuggest Edit

ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease and certain infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.  Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.

TypePublic
Founded2004
HQRamsey, US
Websiteadmabiologics.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Dec 2018)314(+8%)
Revenue (FY, 2018)$17 M(-25%)
Share Price (Oct 2019)$4.3 (+5%)

Key People/Management at ADMA Biologics

Bryant E. Fong

Bryant E. Fong

Director
Dov Goldstein

Dov Goldstein

Director
James Mond

James Mond

Chief Scientific and Medical Officer
Brian Lenz

Brian Lenz

Vice President, Chief Financial Officer
Eric I. Richman

Eric I. Richman

Director & Chairperson
Jerrold B. Grossman

Jerrold B. Grossman

Founder and Vice Chairman
Show more

ADMA Biologics Office Locations

ADMA Biologics has offices in Ramsey and Boca Raton
Ramsey, US (HQ)
465 NJ-17, Ramsey, NJ 07446, USA
Boca Raton, US
5800 Park of Commerce Blvd
Show all (2)

ADMA Biologics Financials and Metrics

ADMA Biologics Revenue

ADMA Biologics's revenue was reported to be $16.99 m in FY, 2018
USD

Revenue (Q2, 2019)

6.6m

Net income (Q2, 2019)

(13.2m)

EBIT (Q2, 2019)

(11.3m)

Market capitalization (16-Oct-2019)

257.4m

Closing stock price (16-Oct-2019)

4.3

Cash (30-Jun-2019)

73.6m

EV

251.3m
ADMA Biologics's current market capitalization is $257.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

3.1m5.9m7.2m10.7m22.8m17.0m

Revenue growth, %

93%21%49%

General and administrative expense

4.4m6.7m8.5m18.1m22.5m

R&D expense

9.3m7.0m7.7m6.2m3.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

1.1m1.6m1.5m1.4m1.5m1.3m1.9m2.1m2.3m2.9m2.6m3.4m4.7m4.0m4.7m4.2m3.5m6.6m

General and administrative expense

845.3k1.1m1.5m1.0m1.3m1.4m2.1m1.7m1.7m1.8m4.3m4.4m4.2m5.0m5.0m5.4m5.6m6.1m

R&D expense

1.4m4.3m1.8m1.5m1.4m1.5m2.1m2.0m3.4m1.7m1.2m1.4m1.8m1.3m1.5m1.3m870.6k517.0k

Operating expense total

3.6m7.2m5.1m4.4m4.7m4.8m6.5m6.3m7.8m6.7m8.6m11.8m19.2m20.6m18.1m18.0m16.7m17.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

26.1m17.2m10.4m9.9m43.1m22.8m

Accounts Receivable

384.0k924.5k1.0m3.9m1.4m

Inventories

1.7m1.7m3.4m5.0m12.6m18.6m

Current Assets

31.1m24.1m21.3m21.7m63.2m44.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

5.4m26.5m17.9m14.0m16.6m7.8m9.2m8.9m12.5m7.9m8.5m25.6m13.6m26.1m55.2m42.4m16.5m73.6m

Accounts Receivable

335.1k484.4k803.5k562.2k351.4k522.5k1.2m944.0k826.7k1.3m839.9k2.3m1.5m3.7m3.8m4.1m1.3m5.1m

Inventories

1.2m984.5k1.1m1.5m1.9m2.5m2.8m4.0m4.2m4.6m5.3m13.2m13.4m12.4m12.2m13.9m18.4m23.6m

Current Assets

7.1m30.8m26.5m22.6m31.0m27.1m25.2m17.4m29.5m25.4m15.7m44.3m31.4m46.4m73.6m62.5m38.3m103.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(15.5m)(16.8m)(18.0m)(19.5m)(43.8m)(65.7m)

Depreciation and Amortization

210.6k247.9k469.8k469.6k2.7m3.4m

Inventories

(403.5k)(39.7k)(1.7m)(1.6m)589.3k(6.0m)

Accounts Payable

1.6m(937.8k)308.7k476.8k2.8m(20.5k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(2.7m)(5.9m)(9.9m)(13.2m)(3.6m)(8.3m)(13.4m)(4.6m)(10.6m)(15.0m)(6.5m)(30.8m)(17.8m)(32.6m)(47.7m)(13.1m)(26.3m)

Depreciation and Amortization

96.9k151.1k234.7k352.6k234.4k351.7k118.1k1.2m829.5k1.7m2.5m805.3k1.6m

Inventories

556.5k216.5k1.9m(744.1k)(1.1m)4.0m(763.6k)(1.2m)(288.3k)(201.5k)189.4k381.2k(1.2m)(25.3k)(5.2m)

Accounts Payable

(369.8k)(265.8k)1.8m(305.5k)311.9k2.5m1.0m689.4k1.3m5.2m(202.8k)(2.8m)(653.2k)(420.6k)887.8k
USDY, 2019

EV/EBIT

-22.2 x

EV/CFO

-7.6 x

Financial Leverage

3.1 x
Show all financial metrics

ADMA Biologics Online and Social Media Presence

Embed Graph

ADMA Biologics News and Updates

ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient pa…

ADMA Biologics Announces Data Presented at IDWeek 2019

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics f…

ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures and markets three approved plasma-derived biologics for th…

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, June 6, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of ADMA Biologics, Inc. (NASDAQ: ADMA). If you are...

ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock

RAMSEY, N.J. and BOCA RATON, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for…

ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections

Fifth Patent Issued to the Company in the U.S. Provides Coverage for Expanding the Company’s Hyperimmune IVIG Portfolio Through 2037 Fifth Patent Issued to the Company in the U.S. Provides Coverage for Expanding the Company’s Hyperimmune IVIG Portfolio Through 2037
Show more

ADMA Biologics Blogs

ADMA Biologics Announces Poster Presentation at IDWeek 2019

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 03, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics f…

ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics …

ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics f…

ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®

All Aspects of the Biotest Therapy Business Unit (“BTBU”) Acquisition Are Successfully Completed RAMSEY, N.J. and BOCA RATON, Fla., July 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty …

ADMA Biologics Reports First Quarter 2019 Financial Results

RAMSEY, N.J. and BOCA RATON, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics f…

ADMA Biologics Elects to Draw-Down $27.5 Million in Capital from Existing Perceptive Advisors Credit Agreement

Perceptive Advisors Provides Additional Funding Tranche Commitment of $12.5 Million Available Upon FDA Approval of BIVIGAM® RAMSEY, N.J. and BOCA RATON, Fla., May 03, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopha…
Show more

ADMA Biologics Frequently Asked Questions

  • When was ADMA Biologics founded?

    ADMA Biologics was founded in 2004.

  • Who are ADMA Biologics key executives?

    ADMA Biologics's key executives are Bryant E. Fong, Dov Goldstein and James Mond.

  • How many employees does ADMA Biologics have?

    ADMA Biologics has 314 employees.

  • What is ADMA Biologics revenue?

    Latest ADMA Biologics annual revenue is $17 m.

  • What is ADMA Biologics revenue per employee?

    Latest ADMA Biologics revenue per employee is $54.1 k.

  • Who are ADMA Biologics competitors?

    Competitors of ADMA Biologics include Array BioPharma, Amicus Therapeutics and BTG.

  • Where is ADMA Biologics headquarters?

    ADMA Biologics headquarters is located at 465 NJ-17, Ramsey, NJ 07446, USA, Ramsey.

  • Where are ADMA Biologics offices?

    ADMA Biologics has offices in Ramsey and Boca Raton.

  • How many offices does ADMA Biologics have?

    ADMA Biologics has 2 offices.